-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SomaLogic (SLGC) and Its Rivals Head to Head Contrast
SomaLogic (SLGC) and Its Rivals Head to Head Contrast
SomaLogic (NASDAQ:SLGC – Get Rating) is one of 42 publicly-traded companies in the "Commercial physical research" industry, but how does it compare to its peers? We will compare SomaLogic to similar companies based on the strength of its valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.
Analyst Ratings
This is a breakdown of current ratings and target prices for SomaLogic and its peers, as provided by MarketBeat.
Get SomaLogic alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SomaLogic | 0 | 0 | 4 | 0 | 3.00 |
SomaLogic Competitors | 42 | 621 | 1215 | 24 | 2.64 |
SomaLogic presently has a consensus price target of $12.20, suggesting a potential upside of 278.88%. As a group, "Commercial physical research" companies have a potential upside of 51.29%. Given SomaLogic's stronger consensus rating and higher probable upside, analysts clearly believe SomaLogic is more favorable than its peers.
Institutional and Insider Ownership
59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all "Commercial physical research" companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by company insiders. Comparatively, 11.9% of shares of all "Commercial physical research" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.Volatility & Risk
SomaLogic has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's peers have a beta of 5.23, suggesting that their average stock price is 423% more volatile than the S&P 500.
Profitability
This table compares SomaLogic and its peers' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SomaLogic | -114.46% | -16.76% | -14.61% |
SomaLogic Competitors | -239.39% | -12.45% | -6.19% |
Earnings & Valuation
This table compares SomaLogic and its peers gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
SomaLogic | $81.63 million | -$87.55 million | -3.88 |
SomaLogic Competitors | $2.80 billion | $97.54 million | -15.21 |
SomaLogic's peers have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
SomaLogic beats its peers on 7 of the 13 factors compared.
SomaLogic Company Profile
(Get Rating)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.
SomaLogic (NASDAQ:SLGC – Get Rating) is one of 42 publicly-traded companies in the "Commercial physical research" industry, but how does it compare to its peers? We will compare SomaLogic to similar companies based on the strength of its valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.
SomaLogic(纳斯达克代码:SLGC-GET Rating)是商业物理研究行业42家上市公司之一,但与同行相比如何?我们将根据SomaLogic的估值、盈利能力、风险、机构所有权、分析师建议、收益和股息等方面的实力,将SomaLogic与类似公司进行比较。
Analyst Ratings
分析师评级
This is a breakdown of current ratings and target prices for SomaLogic and its peers, as provided by MarketBeat.
这是由MarketBeat提供的SomaLogic及其同行的当前评级和目标价格细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SomaLogic | 0 | 0 | 4 | 0 | 3.00 |
SomaLogic Competitors | 42 | 621 | 1215 | 24 | 2.64 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
SomaLogic | 0 | 0 | 4 | 0 | 3.00 |
SomaLogic竞争对手 | 42 | 621 | 1215 | 24 | 2.64 |
SomaLogic presently has a consensus price target of $12.20, suggesting a potential upside of 278.88%. As a group, "Commercial physical research" companies have a potential upside of 51.29%. Given SomaLogic's stronger consensus rating and higher probable upside, analysts clearly believe SomaLogic is more favorable than its peers.
SomaLogic目前的普遍目标价为12.20美元,暗示潜在上涨278.88%。作为一个群体,“商业物理研究”公司有51.29%的潜在上行空间。考虑到SomaLogic更高的共识评级和更高的可能上行空间,分析师们显然认为SomaLogic比它的同行更有利。
Institutional and Insider Ownership
机构和内部人持股
Volatility & Risk
波动性与风险
SomaLogic has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's peers have a beta of 5.23, suggesting that their average stock price is 423% more volatile than the S&P 500.
SomaLogic的贝塔系数为1.53,这表明其股价的波动性比标准普尔500指数高53%。相比之下,SomaLogic的贝塔系数为5.23,这表明它们的平均股价波动性比标准普尔500指数高出423%。
Profitability
盈利能力
This table compares SomaLogic and its peers' net margins, return on equity and return on assets.
此表比较了SomaLogic及其同行的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
SomaLogic | -114.46% | -16.76% | -14.61% |
SomaLogic Competitors | -239.39% | -12.45% | -6.19% |
净利润率 | 股本回报率 | 资产回报率 | |
SomaLogic | -114.46% | -16.76% | -14.61% |
SomaLogic竞争对手 | -239.39% | -12.45% | -6.19% |
Earnings & Valuation
收益与估值
This table compares SomaLogic and its peers gross revenue, earnings per share and valuation.
此表比较了SomaLogic及其同行的毛收入、每股收益和估值。
Gross Revenue | Net Income | Price/Earnings Ratio | |
SomaLogic | $81.63 million | -$87.55 million | -3.88 |
SomaLogic Competitors | $2.80 billion | $97.54 million | -15.21 |
总收入 | 净收入 | 市盈率 | |
SomaLogic | 8163万美元 | -8,755万元 | -3.88 |
SomaLogic竞争对手 | 28亿美元 | 9754万美元 | -15.21 |
SomaLogic's peers have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
SomaLogic的同行比SomaLogic的收入和收益更高。SomaLogic的市盈率高于其同行,这表明它目前的价格高于同行业的其他公司。
Summary
摘要
SomaLogic beats its peers on 7 of the 13 factors compared.
SomaLogic在比较的13个因素中有7个超过了同行。
SomaLogic Company Profile
SomaLogic公司简介
(Get Rating)
(获取评级)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
SomaLogic公司是美国的一家蛋白质生物标记物发现和临床诊断公司。它开发慢速修饰适体(SOMAmers),这是一种针对其同源蛋白质的改良核酸蛋白质结合试剂;并提供专有的SomaScan服务,提供复杂生物样本中的多重蛋白质检测和蛋白质水平的量化。该公司的SOMAmers/SomaScan技术使研究人员能够分析各种类型的生物样本以寻找蛋白质生物标记物签名,这可用于药物发现和开发。其SomaScan的生物标志物发现有助于在各种疾病领域的诊断应用,包括心血管和代谢性疾病、非酒精性脂肪性肝炎、健康等。该公司还提供SomaSignal仅用于研究和实验室开发的测试。它以制药和生物技术公司以及学术研究机构为重点,为研究和临床客户提供服务,并通过评估蛋白质-蛋白质和蛋白质-基因网络,促进药物开发、临床试验分析和新的人类生物学见解。该公司成立于1999年,总部设在科罗拉多州博尔德市。
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.
接受SomaLogic日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SomaLogic和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧